Trial · NCT02375828
Glibentek in Patients With Neonatal Diabetes Secondary to Mutations in K+-ATP Channels
NCT02375828, Phase 3, Completed, Assistance Publique - Hôpitaux de Paris
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Glibentek in Patients With Neonatal Diabetes Secondary to Mutations in K+-ATP Channels. Trials, record NCT02375828. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02375828
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Glibentek in Patients With Neonatal Diabetes Secondary to Mutations in K+-ATP Channels
- NCT number
- NCT02375828
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 10 participants, actual
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Conditions
- Neonatal Diabetes Secondary to Mutation in the Potassium Channel
- Interventions
- Glibenclamide
- First posted
- 2015-03-03
- Last updated
- 2025-09-08
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Acceptability of an oral solution of glibenclamide (Hedonic visual scale) | 2 months after the change from pills to oral solution. | Hedonic visual scale |
| Primary | Acceptability of an oral solution of glibenclamide (Hedonic visual scale) | 3 months after the change from pills to oral solution. | Hedonic visual scale |
| Secondary | Tolerance of an oral solution of glibenclamide (Self administrated questionnaries) | 2 months after the change from pills to oral solution. | Self administrated questionnaries, liver and renal biology |
| Secondary | Tolerance of an oral solution of glibenclamide (Self administrated questionnaries) | 3 months after the change from pills to oral solution. | Self administrated questionnaries, liver and renal biology |
| Secondary | Recording pharmaceutical data on pills and oral solution of glibenclamide (Blood drug dosage) | At inclusion | Blood drug dosage |
| Secondary | Recording pharmaceutical data on pills and oral solution of glibenclamide (Blood drug dosage) | 2 months after the switch from pills to oral solution | Blood drug dosage |
| Secondary | No alteration in metabolic control of the disease | During the first month of administration | HbA1C at month 3, fructosamine at month 2 and 3, self record of hypoglycaemia during month 1, 2 and 3, glycemia before and after meals during 2 consecutive days at introduction of oral solution and during 2 meals at month 2 and month 3 |
| Secondary | No alteration in metabolic control of the disease | 2 months after the change from pills to oral solution | HbA1C at month 3, fructosamine at month 2 and 3, self record of hypoglycaemia during month 1, 2 and 3, glycemia before and after meals during 2 consecutive days at introduction of oral solution and during 2 meals at month 2 and month 3 |
| Secondary | No alteration in metabolic control of the disease | 3 months after the change from pills to oral solution | HbA1C at month 3, fructosamine at month 2 and 3, self record of hypoglycaemia during month 1, 2 and 3, glycemia before and after meals during 2 consecutive days at introduction of oral solution and during 2 meals at month 2 and month 3 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02375828
GET https://conductscience.org/api/trials/v1/NCT02375828/registered